Linical Co., Ltd.

As of March 31, 2025, Linical Co., Ltd. carries a market capitalization of 7.23B, placing it among publicly traded companies globally. Its enterprise value stands at 2.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Linical Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2025, Linical Co., Ltd. has 22.59M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Linical Co., Ltd. maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Linical Co., Ltd. recorded 54.69M in income tax expense.

As of the close on October 23, 2026, Linical Co., Ltd.'s stock has declined approximately 40.83% over the past 52 weeks. The 50-day moving average sits at 204.62, while the 200-day moving average is 244.83.

As of March 31, 2025, Linical Co., Ltd. holds 7.04B in cash and equivalents against 2.33B in total debt, resulting in a net debt position of -4.94B. Total book value stands at 7.25B, with working capital of 4.15B providing operational flexibility.

Linical Co., Ltd.'s most recent stock split took place on December 28, 2015 with a 1:2 split ratio.